Lifecore Biomedical Inc
NASDAQ:LFCR

Watchlist Manager
Lifecore Biomedical Inc Logo
Lifecore Biomedical Inc
NASDAQ:LFCR
Watchlist
Price: 4.05 USD 0.75%
Market Cap: $151.8m

Wall Street
Price Targets

LFCR Price Targets Summary
Lifecore Biomedical Inc

Wall Street analysts forecast LFCR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LFCR is 8.93 USD with a low forecast of 7.58 USD and a high forecast of 10.5 USD.

Lowest
Price Target
7.58 USD
87% Upside
Average
Price Target
8.93 USD
120% Upside
Highest
Price Target
10.5 USD
159% Upside
Lifecore Biomedical Inc Competitors:
Price Targets
CMCO
Columbus McKinnon Corp
85% Upside
ISRG
Intuitive Surgical Inc
33% Upside
TPFG
Property Franchise Group PLC
52% Upside

Revenue
Forecast

-7% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
-7% / Year
Past Growth
7% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

For the last 13 years the compound annual growth rate for Lifecore Biomedical Inc's revenue is -7%. The projected CAGR for the next 4 years is 7%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-18%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-18%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LFCR's stock price target?
Price Target
8.93 USD

According to Wall Street analysts, the average 1-year price target for LFCR is 8.93 USD with a low forecast of 7.58 USD and a high forecast of 10.5 USD.

What is Lifecore Biomedical Inc's Revenue forecast?
Projected CAGR
7%

For the last 13 years the compound annual growth rate for Lifecore Biomedical Inc's revenue is -7%. The projected CAGR for the next 4 years is 7%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett